In the race to develop drugs to treat
Horizon Discovery recently announced their partnership with the Michael J Fox foundation and the development of their new rodent model of parkinson's disease.
We spoke with Andrew Brown, Product Manager at Horizon Discovery, to find out more:
1. What are the current challenges with Parkinson’s research?
AB: Researchers rely on tools, including pre-clinical models, to understand the cause and mechanisms underlying Parkinson's disease and to develop effective treatments. When such tools are lacking, investigators must often make their own, wasting time and resources that would be better spent studying Parkinson's disease. Many existing tools also may lack sufficient quality control data, are difficult to obtain by the broader research community, or may come with restrictive license terms and fees that hinder drug makers' ability to use them. Promoting the generation and availability of these critical research tools is a key way MJFF accelerates therapeutic development for Parkinson's patients.
